Lv1
38 积分 2024-12-24 加入
Intravesical therapy with the trifunctional anti-EpCAM/CD3 bsAb Catumaxomab is well tolerated and shows encouraging preliminary efficacy in patients with high-risk
3小时前
待确认
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
4小时前
已完结
Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus
19天前
已完结
T cell-engaging therapies — BiTEs and beyond
25天前
已完结
Cancer-fighting immune cells could soon be engineered inside our bodies
1个月前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
2个月前
已完结
A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
2个月前
已完结
Improving early phase oncology clinical trial design: A case study
2个月前
已完结
ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
3个月前
已完结
皖公网安备34019202002308
